VANGUARD TOTAL STOCK MARKET INDEX FUND 152,819.
IMS HEALTH MONEYHOUSE FULL
Please read full disclosures and analyst background at before investing. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The Firm does not accept any equity compensation.
We received $39,500 from the Company for 4 quarterly Research Reports with coverage commencing on. The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. Its 30 analysts are primarily CFAs and have expertise in many industries. While we believe management is actively pursuing the issues surrounding its clinical programs, we are considerably concerned regarding the long-term for this company.ĭutton Associates is one of the largest independent investment research firms in the U.S. if it is successful in reversing the not approvable status of its erectile dysfunction product with the FDA when they meet on October 15, 2008, NexMed would be eligible to receive a milestone payment from Warner Chilcott.
IMS HEALTH MONEYHOUSE TRIAL
The European comparator study is continuing and top-line data will be available in early 2009, and NexMed expects Novartis to file for regulatory approval in Europe if data from this trial are positive. Specifically, receipt of an approved patent claim from the US Patent Office would generate the previously- agreed upon $3.5 million milestone payment. Novartis' decision regarding filing of a New Drug Application in the US does not affect other parts of the collaboration agreement. Novartis' announcement followed the recent completion of two double-blind, placebo controlled Phase 3 clinical trials conducted in the US,Įurope, Canada and Iceland. The clinical product being investigated under this agreement is NexMed's anti-fungal topical nail solution for the treatment of fungal nail infections (onychomycosis) affecting toenails and/or fingernails, known as NM100060 (terbinafine 10% topical formulation). NexMed shares fell in excess of 80% over the past week in response to news that its collaboration partner, Novartis AG (NYSE:NVS - News), announced that it would not seek to file a New Drug Application with the US Food and Drug Administration (FDA). The research note by Dutton senior analyst Denise Resnik, MS is available at as well as from First Call, Bloomberg, FactSet, Capital IQ, Zacks, Reuters, Knobias, and other leading financial portals. ROSEVILLE, Calif.-(BUSINESS WIRE)-Dutton Associates updates its coverage of NexMed (Nasdaq:NEXM - News), lowering its rating to Speculative Buy and a $1.00 price target.
0 kommentar(er)
